TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

50:1-26. 14A.49 Schuster FL et al. Opportunistic amoebae: prophylaxis and treatment. Drug Resist Updates 2004;7: 41-51. 14A.50 Schuster FL et al. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. Int J Parasitol 2004;34:1001-27. 14A.51 Schuster FL et al. In vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp. and Naegleria fowleri. J Eukaryot Microbiol 2006;53:121-6. 14A.52 Schuster FL et al. Under the radar: Balamuthia amebic encephalitis. Clin Infect Dis 2009;48:879-87. 14A.53 Matin A et al. Increasing importance of Balamuthia mandrillaris. Clin Microbiol Rev 2008;21:435-48. 14A.54 Jung S et al. Balamuthia mandrillaris meningoencephalitis in an immunocompetent patient. Arch Pathol Lab Med 2004;128:466-8. 14A.55 Marciano-Cabral F et al. Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev 2003;16:273-307. 14A.56 Singhal T et al. Successful treatment of Acanthamoeba meningitis with combination oral antimicrobials. Pediatr Infect Dis J 2001;20:623-7. 14A.57 Deetz TR et al. Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases. Clin Infect Dis 2003;37:1304-12. 14A.58 Slater CA et al. Successful treatment of disseminated Acanthamoeba infection in an immuno-compromised patient. N Engl J Med 1994;331:85-7. 14A.59 Kim JH et al. Effect of therapeutic chemical agents in vitro and on experimental meningoen-cephalitis due to Naegleria fowleri. Antimicrob Agents Chemother 2008;52:4010-6. 14A.60 Vargas-Zepeda J et al. Successful treatment of Naegleria fowleri meningoencephalitis by using intravenous amphotericicn B, fluconazole and rifampicin. Arch Med Res 2005;36:83-6. 14A.61 Soltow SM et al. Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. Antimicrob Agents Chemother 2007;51:23-7. 14A.62 Gelman BB et al. Amoebic encephalitis due to Sappinia diploidea. J Am Med Assoc 2001;285:2450- 1. 14A.63 Wormser GP et al. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. Clin Infect Dis 2010;50:381-6. 14A.64 Vannier E et al. Human babesiosis. Infect Dis Clin North Am 2008;22:469-88. 14A.65 Kuwayama DP et al. Spontaneous splenic rupture caused by Babesia microti infection. Clin Infect Dis 2008;46:e92-5. 14A.66 Wormser GP et al. The clinical assessment, treatment and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43:1089-134. 14A.67 Krause PJ. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 2008;46:370-6. 14A.68 Powell VI et al. Exchange transfusion for malaria and Babesia infection. Transfus Med Rev 2002;16: 239-50. 14A.69 Krause PJ et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med 2000; 343:1454-8. 14A.70 Schriefer A et al. Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis. Curr Opin Infect Dis 2008;21:483-8. 14A.71 Murray HW et al. Advances in leishmaniasis. Lancet 2005;366:1561-77. 14A.72 Croft SL et al. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006;19:111-26. 14A.73 van Griensven J et al. Combination therapy for visceral leishmaniasis. Lancet Infect Dis 2010;10: 184-94. 14A.74 Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 2001;45:2185-97. 14A.75 Bern C et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006;43:917-24. 14A.76 Sundar S et al. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis 2007;45:556-61. 14A.77 Sundar S et al. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin Infect Dis 2006;42:608-13. 14A.78 Murray HW. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev Anti Infect Ther 2004;2:279-92. 14A.79 den Boer M et al. Treatment options for visceral leishmaniasis. Expert Rev Anti Infect Ther 2006;4: 187-97. 14A.80 Olliaro PL et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 2005;5:763-74. 14A.81 Antinori S et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008;8:191-9. 14A.82 Murray HW. Kala-azar. Progress against a neglected disease. N Engl J Med 2002;347:1793-4. 14A.83 Davidson RN et al. Short course treatment of visceral leishmaniasis with liposomal amphotericin B. Clin Infect Dis 1996;22:938-43. 14A.84 Sundar S et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010;362:504-12. 14A.85 Sundar S et al. Short course, low dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997;127:133-7. 14A.86 di Martino L et al. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J Pediatr 1997;131:271-7. 14A.87 Syriopoulo V et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 2003;36:560-6. 14A.88 Jacobs S. An oral drug for leishmaniasis. N Engl J Med 2002;347:1737-8. 14A.89 Sundar S et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46. 14A.90 Sundar S et al. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 2003;22:434-8. 14A.91 Soto J et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001;33:e57-61. 14A.92 Lira R et al. Evidence that high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony resistant strains of Leishmania donovani. J Infect Dis 1999;180:564-7.
14A.93 Sundar S et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008;47:1000-6. 14A.94 Thakur CP. Sodium antimony gluconate, amphotericin and myocardial damage. Lancet 1998;351: 1928-9. 14A.95 Sundar S et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007;356: 2571-81. 14A.96 Sundar S et al. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21day treatment. Clin Infect Dis 2009;49:914-8. 14A.97 Blum J et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 2004;53:158-66. 14A.98 Schwartz E et al. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 2006;6:342-9. 14A.99 Reithinger R et al. Cutaneous leishmaniasis. Lancet Infect Dis 2007;7:581-96. 14A.100 Magill AJ. Cutaneous leishmaniasis in the returning traveller. Infect Dis Clin North Am 2005;19:241- 66. 14A.101 Minodier P et aL. Cutaneous leishmaniasis treatment. Travel Med Infect Dis 2007;5:150-8. 14A.102 Hepburn NC. Cutaneous leishmaniasis: current and future management. Expert Rev Anti Infect Ther 2003;1:563-70. 14A.103 Goto H et al. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010;8:419-33. 14A.104 Schwartz E et al. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 2006;6:342-9. 14A.105 Arevalo J et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 2007;195:1846-51. 14A.106 Rojas R et al. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis 2006;193:1375-83. 14A.107 Miranda-Verastegui C et al. First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Neglected Trop Dis 2009; 3:e491. 14A.108 Arevalo I et al. Successful treatment of drug resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001;33:1847-51. 14A.109 Arevalo I et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 2007;44:1549-54. 14A.110 Machado PR et al. Oral pentoxyfilline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 2007;44:788-93. 14A.111 Santos JB et al. Antimony plus recombinant human granulocyte macrophage colony stimulating factor applied topically in low doses enhances healing of cutaneous leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. J Infect Dis 2004;190:1793-6. 14A.112 Soto J et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004;38:1266-72. 14A.113 Soto J et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007;44: 350-6. 14A.114 Soto J et al. Short report: efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. Am J Trop Med Hyg 2009;81:387-9. 14A.115 Reithinger R et al. Cutaneous leishmaniasis. Lancet Infect Dis 2007;7:581-96. 14A.116 Blum J et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 2004;53:158-66. 14A.117 Crogan J et al. Management of Old World cutaneous leishmaniasis in refugee children. Pediatr Infect Dis J 2010;29:357-9. 14A.118 Goto H et al. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010;8:419-33. 14A.119 Alrajhi AA et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002;346:891-5. 14A.120 World Health Organization. Guidelines for the treatment of malaria (second edition). Available at: http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf. Accessed on August 11th 2010. 14A.121 Rogerson SJ et al. Treatment and prevention of malaria in pregnancy: opportunities and challenges. Expert Rev Anti Infect Ther 2006;4:687-702. 14A.122 Nosten F et al. Case management of malaria in pregnancy. Lancet Infect Dis 2007;7:118-25. 14A.123 Ward SA et al. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis 2007;7:136-44. 14A.124 Alvarez JR et al. Malaria in pregnancy. Infect Dis Obstet Gynecol 2005;13:229-36. 14A.125 Tagbor H et al. Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. Lancet 2006; 368:1349-56. 14A.126 McGready R et al. Malaria and the pregnant traveller. Travel Med Infect Dis 2004;2:127-42. 14A.127 Crawley J et al. Malaria in children. Lancet 2010;375:1468-81. 14A.128 Stauffer W et al. Diagnosis and treatment of malaria in children. Clin Infect Dis 2003;37:1340-8. 14A.129 Lalloo DG et al. Malaria in adolescence: burden of disease, consequences, and opportunities for intervention. Lancet Infect Dis 2006;6:780-93. 14A.130 Bell DJ et al. Treatment of childhood Plasmodium falciparum malaria: current challenges. Expert Rev Anti Infect Ther 2007;5:141-52. 14A.131 Baird JK. Effectiveness of antimalarial drugs. N Engl J Med 2005;352:1565-77. 14A.132 Stauffer WM et al. Diagnostic performance of rapid diagnostic tests versus blood smears for malaria in US clinical practice. Clin Infect Dis 2009;49:908-13. 14A.133 Murray CK et al. Update on rapid diagnostic testing for malaria. Clin Microbiol Rev 2008;21:97-110. 14A.134 Griffith KS et al. Treatment of malaria in the United States. A systematic review. J Am Med Assoc 2007;297:2264-77. 14A.135 Whitty CJ et al. Malaria: an update on treatment of adults in non-endemic countries. Br Med J 2006; 333:241-5. 14A.136 Ashley E et al. Malaria. Travel Med Infect Dis 2006;4:159-73. 14A.137 Greenwood BM et al. Malaria. Lancet 2005;365:1487-98. 14A.138 White NJ. The treatment of malaria. N Engl J Med 1996;335:800-6. 14A.139 Collins WE et al. Plasmodium malariae: parasite and disease. Clin Microbiol Rev 2007;20:579-92. 14A.140 Daneshvar C et al. Clinical and laboratory features of human Plasmodium knowlesi infection. Clin Infect Dis 2009;49:852-60. 14A.141 Putaporntip C et al. Differential prevalence of Plasmodium infections and cryptic Plasmodium knowle-
Page 1 and 2:
TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4:
1.89 Laupland KB. Vascular and para
Page 5 and 6:
of NICE guidance. Br Med J 2008;337
Page 7 and 8:
tions à Clostridium difficile dans
Page 9 and 10:
sis of placebo-controlled trials. C
Page 11 and 12:
1.446 Centers for Disease Control a
Page 13 and 14: 1.532 Olaison L et al. Enterococcal
Page 15 and 16: 1.615 Muder RR et al. Isolation of
Page 17 and 18: 2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20: 2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22: 1.873 Korting HC et al. Current top
Page 23 and 24: 1.970 Thomas RJ et al. Current mana
Page 25 and 26: of severe respiratory failure. Clin
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63: new prediction equation. Ann Intern
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77 and 78: tients. J Antimicrob Chemother 2009
Page 79 and 80: duct characteristics. Available at:
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86: North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88: 1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90: 21.358 Calabrese LH et al. Viral Ar
Page 91 and 92: 24. 21.452 Jeha LE et al. Long term
Page 93 and 94: induced functional androgen deficie
Page 95 and 96: 25A.27 Conseil Supérieur de la San
Page 97 and 98: product characteristics. Available
Page 99 and 100: mortality after kidney transplantat
Page 101 and 102: 33A.1 Kearney BP et al. The penetra
Page 103 and 104: Clin Plast Surg Clinics in Plastic
Page 105 and 106: Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?